Location of Repository

The Use of Mouse Models for Understanding the Biology of Down Syndrome and Aging

By Guido N. Vacano, Nathan Duval and David Patterson

Abstract

Down syndrome is a complex condition caused by trisomy of human chromosome 21. The biology of aging may be different in individuals with Down syndrome; this is not well understood in any organism. Because of its complexity, many aspects of Down syndrome must be studied either in humans or in animal models. Studies in humans are essential but are limited for ethical and practical reasons. Fortunately, genetically altered mice can serve as extremely useful models of Down syndrome, and progress in their production and analysis has been remarkable. Here, we describe various mouse models that have been used to study Down syndrome. We focus on segmental trisomies of mouse chromosome regions syntenic to human chromosome 21, mice in which individual genes have been introduced, or mice in which genes have been silenced by targeted mutagenesis. We selected a limited number of genes for which considerable evidence links them to aspects of Down syndrome, and about which much is known regarding their function. We focused on genes important for brain and cognitive function, and for the altered cancer spectrum seen in individuals with Down syndrome. We conclude with observations on the usefulness of mouse models and speculation on future directions

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier: oai:pubmedcentral.nih.gov:3296169
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (2011). A .D u c h o n ,M .R a v e a u ,C .C h e v a l i e r ,V .N a l e s s o
    2. (2005). A .J .V i l l a r ,P .V .B e l i c h e n k o ,A .M .G i l l e s p i e ,H .M .K o z y
    3. (2004). A chromosome 21 critical region does not cause specific down syndrome phenotypes,”
    4. (2008). A humanized mouse model for the reduced folate carrier,”
    5. (2010). A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions,”
    6. (1996). A n d e r s o n ,R .G .O s h i m a ,a n dR .A .M a k i ,“ P U . 1b u tn o tE t s -2 is essential for macrophage development from embryonic stem cells,”
    7. (1997). a n o ,C .E r n e s t o ,R .G .T h o m a se ta l . ,“ Ac o n t r o l l e d trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease,” New England
    8. (2011). A noradrenergic lesion exacerbates neurodegeneration in a down syndrome mouse model,”
    9. (2010). A novel transgenic mouse model of CBS-deficient homocystinuria does not incur hepatic steatosis or fibrosis and exhibits a hypercoagulative phenotype that is ameliorated by betaine treatment,”
    10. (1974). A.Gropp,D.Giers,andU.Kolbus,“Trisomyinthefetalbackcross progeny of male and female metacentric heterozygotes of the mouse.
    11. (2003). A.M.Cataldo,S.Petanceska,C.M.Peterhoffetal.,“Appgene dosage modulates endosomal abnormalities of Alzheimer’s disease in a segmental trisomy 16 mouse model of Down syndrome,”
    12. (2008). Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test,”
    13. (2009). Agedependent dysregulation of brain amyloid precursor protein in the Ts65Dn Down syndrome mouse model,”
    14. (1996). AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis,”
    15. (2011). An increase in basal BDNF provokes hyperactivation of the Akt-Mammalian target of rapamycin pathway and deregulationoflocaldendritictranslationinamousemodelofdown’s syndrome,”
    16. (1981). Animal models for autosomal trisomy,” in Trisomy 21 (Down Syndrome),F .F .d el aC r u za n dP
    17. (2010). Apoptosis is directly related to intracellular amyloid accumulation in a cell line derived from the cerebral cortex of a trisomy 16 mouse, an animal model of Down syndrome,”
    18. (2006). APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy,”
    19. (2010). APP transgenic modeling of Alzheimer’s disease: mechanisms of neurodegeneration and aberrant neurogenesis,”
    20. (1995). Assignment of the human folate transporter gene to chromosome 21q22.3 by somatic cell hybrid analysis and in situ hybridization,”
    21. (2004). Aβ is targeted to the vasculature in a mouse model of hereditary18 Current Gerontology and Geriatrics Research cerebral hemorrhage with amyloidosis,”
    22. (1995). B a r n e s ,G .L .B r o d s k y ,G .J .B a r e l a ,J .H .B l e s k a n ,a n d D. Patterson, “Development of a mouse model for the study of human purine metabolism,”
    23. (2011). B l a z e k ,A .G a d d y ,R .M e y e r ,R .J .R o p e r ,a n dJ . Li, “Disruption of bone development and homeostasis by trisomy
    24. (2010). B vitamins and the aging brain,”
    25. (2011). Behavioral characterization of a mouse model overexpressing DSCR1/RCAN1,”
    26. (2010). BehavioralvalidationoftheTs65DnmousemodelforDownCurrent Gerontology and Geriatrics Research 17 syndrome of a genetic background free of the retinal degeneration mutation
    27. (2011). Bone density phenotypes in mice aneuploid for the Down syndrome critical region,” American J o urnalo fM edicalG enetics,P artA,vol.155,no.10,pp.2436– 2445,
    28. (2002). Calcineurin as a multifunctional regulator,”
    29. (2008). Characterization of the cardiac phenotype
    30. (2009). Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model,”
    31. Chronic overexpression of the calcineurin inhibitory gene DSCR1 (adapt78) is associated with Alzheimer’s disease,”
    32. (2002). Core-binding factors in haematopoiesis and leukaemia,”
    33. (2004). Cystathionine β-synthase: structure, function, regulation, and location of homocystinuriacausing mutations,”
    34. (1998). Defective trophoblast function in mice with a targeted mutation of
    35. (1996). Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome,”
    36. (2010). Dietary choline reverses some, but not all, effects of folate deficiency on neurogenesis and apoptosis in fetal mouse brain,”
    37. (2001). Down syndrome and alzheimer’s disease: a link between development and aging,”
    38. (2004). Down syndrome and beta-amyloid deposition,” Current Opinion
    39. Down syndrome as a model o fD N Ap o l y m e r a s eb e t ah a p l o i n s u fficiency and accelerated aging,” Mechanisms of Ageing and Development.
    40. (2001). Down syndrome congenital heart disease: a narrowed region and a candidate gene,”
    41. (2005). Down syndrome, drug metabolism,
    42. (2009). Down’s syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1,”
    43. (1994). Down’s syndrome: up-regulation of β-amyloid protein precursor and τ mRNAs and their defective coordination,”
    44. (2000). DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurinmediated signaling pathways,”
    45. (2008). DSCR1/RCAN1 regulates vesicle exocytosis and fusion pore kinetics: implications for Down syndrome and Alzheimer’s disease,”
    46. (2003). Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy,”
    47. (1968). e c h t ,M .P .C a s e ,E .W .L o v r i e n ,J .V .H i g g i n s ,H
    48. (2010). Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice,” Brain Research,
    49. (2010). Enlarged brain ventricles and impaired neurogenesis in the Ts1Cje and Ts2Cje mouse models of down syndrome,”
    50. (2005). ETS transcription factors and their emerging roles in human cancer,”
    51. (2003). Ets2-dependent stromal regulation of mouse mammary tumors,”
    52. (2002). Excessive expression of synaptojanin
    53. (2009). Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of down syndrome,”
    54. (1995). F e r r e r ,a n dX .E s t i v i l l ,“ An e wh u m a ng e n ef r o mt h eD o w n syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart,”
    55. (2010). Fl´ orez et al., “Memantine normalizes several phenotypic features in the Ts65Dn mouse model of down syndrome,”
    56. (2008). Folate metabolism and the risk of Down syndrome,” Down’s Syndrome,
    57. (1999). G.R.Seabrook,D.W.Smith,B.J.Boweryetal.,“Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein,”
    58. (2000). Gajic et al., “Mice with combined gene knock-outsrevealessentialandpartiallyredundantfunctions of amyloid precursor protein family members,”
    59. (2004). Gene expression from the aneuploid chromosomeinatrisomymousemodelofDownsyndrome,”
    60. (1999). Gene expression relevant to Down syndrome: problems and approaches,”
    61. (2009). Gene expression signatureofcerebellarhypoplasiainamousemodelofDown syndrome during postnatal development,”
    62. (1980). Genes coding for sensitivity to interferon (IfRec) and soluble superoxide dismutase (SOD-1) are linked in mouse and man and map to
    63. (2005). Genetics: an aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes,”
    64. (2010). Guzm´ a n ,E .L´ opez-Fern´
    65. (1999). Hematopoietic deficiencies and core binding factor expression in murine Ts16, an animal model for Down syndrome,”
    66. (2008). Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome,”
    67. (2009). Identification of independent APP locus duplication in Japanese patients with early-onset Alzheimer disease,”
    68. (2004). Impaired Ptdlns(4,5)P2 synthesis in nerve terminals produces defects in synaptic vesicle trafficking,”
    69. (2006). Increased App expression in a mouse model of Down’s syndrome disrupts NGF transport and causes cholinergic neuron degeneration,”
    70. (2005). Increased dosage of the RUNX1/AML1 gene: a third mode of RUNX leukemia?”
    71. (2011). Increased male reproductive success in
    72. (2011). Increased survival following tumorigenesis in Ts65Dn mice that model down syndrome,”
    73. (2000). Independent signals control expression of the calcineurin inhibitory proteins MCIP1andMCIP2instriatedmuscles,”CirculationResearch,
    74. (2009). ı a ,N .J .M o r a ,F .V .P a l l a r d ´
    75. (2010). J.Gregers,I.J.Christensen,K.Dalhoffetal.,“Theassociation of reduced folate carrier 80G > A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number,”
    76. (2010). J.Moon,M.Chen,S.U.Gandhyetal.,“Perinatalcholinesupplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of down syndrome,”
    77. (2011). K e r n ,K .N .M a c l e a n ,H .J i a n g ,E .Y .S y n d e r ,J .R .S l a d e k
    78. (2006). K no x,J .Bo werso x,S.F orbes,andD .P att erson, “The production of transgenic mice expressing human cystathioninebeta-synthasetostudyDownsyndrome,”Behavior Genetics,
    79. (2009). K o r b e l ,T .T i r o s h - W a g n e r ,A .E .U r b a ne ta l . ,“ T h e genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies,”
    80. (2006). K.Sleegers,N.Brouwers,I.Gijselincketal.,“APPduplication is sufficient to cause early onset Alzheimer’s dementia with cerebral amyloid angiopathy,”
    81. (2010). Lowering betaamyloid levels rescues learning and memory in a Down syndrome mouse model,” PloS one,v o l .5 ,n o .6 ,A r t i c l eI D e10943,
    82. (2010). M.G.Mehedint,C.N.Craciunescu,andS.H.Zeisel,“Maternal dietary choline deficiency alters angiogenesis in fetal mouse hippocampus,”
    83. (2005). M.Yanagida,M.Osato,N.Yamashitaetal.,“Increaseddosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesisinBXH2mice,”Oncogene,vol.24,no.28,pp.
    84. (2003). Metabolic imprinting of choline by its availability during gestation: implications for memory and attentional processing across the lifespan,” Neuroscience and Biobehavioral Reviews,v o l .2 7 ,n o .4 ,p p .
    85. (1996). Mice deficient for the amyloid precursor protein gene,”
    86. (2004). Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down’s syndrome, revealing PRAME as a specific discriminating marker,”
    87. (2006). Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome,”
    88. (2008). Mitochondrial dysfunction in mouse trisomy 16 brain,”
    89. (2010). Molecular basis of pharmacotherapies for cognition in Down syndrome,”
    90. (2011). Molecular characterization of the translocation breakpoints
    91. (1990). Molecular definition of a region of chromosome 21 that causes features of the down syndrome phenotype,”
    92. (2002). Mortality associated with Down’s syndrome in the USA from 1983 to 1997: a population-based study,”
    93. (2003). Mutagenesis of GATA1 is an initiating event
    94. (2000). Mutations in synaptojanin disrupt synaptic vesicle recycling,”
    95. (1999). O.Cremona,G.DiPaolo,M.R.Wenk etal.,“Essentialroleof phosphoinositide metabolism in synaptic vesicle recycling,”
    96. (2008). Oligomeric amyloid-β peptide disrupts phosphatidylinositol-4,5- bisphosphate metabolism,”
    97. (2005). Origins of leukaemia in children with down syndrome,”
    98. (1968). P a n t ,H .W .M o s e r ,a n dS .M .K r a n e ,“ H y p e r u r i c e m i a in Down’s syndrome,”
    99. (2006). Phosphoinositides in cell regulation and membrane dynamics,”
    100. (2010). Polymorphisms in folate-metabolizing genes, chromosome damage, and risk of Down syndrome in Italian women: identification of key factors using artificial neural networks,”
    101. (2007). Possible compensatory events in adult Down syndrome brain prior to the development of Alzheimer disease neuropathology: targets for nonpharmacological intervention,”
    102. (1996). Prevalence of dementia in adults with and without
    103. (2010). Probing the biology of Alzheimer’s disease in mice,”
    104. (1995). R e e v e s ,N .G .I r v i n g ,T .H .M o r a ne ta l . ,“ Am o u s e model for Down syndrome exhibits learning and behaviour deficits,”
    105. (2009). Rapamycin fed late in life extends lifespan in genetically heterogeneous mice,”
    106. (2011). Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice,”
    107. (1997). Rapid phosphorylation of Ets-2 accompanies mitogen-activated protein kinase activation and the induction of heparin-binding epidermal growth factor gene expression by oncogenic
    108. (2002). Ravel-Chapuis et al., “Expression of mutant Ets protein at the neuromuscular synapse causes alterations in morphology and gene expression,”
    109. (1976). Reciprocal translocation, 4q-; 21p+, giving rise to Down’s syndrome,”
    110. (2011). Recruitment of actin modifiers to TrkA endosomes governs retrograde NGF signaling and survival,”
    111. (1994). Regulation of gene expression by transcription factors
    112. (2005). Regulation of ion channels by phosphatidylinositol 4,5-bisphosphate,”
    113. (2009). required for endothelial cell survival during embryonic angiogenesis,”
    114. (2005). Restoration of DSCR1 to disomy in the trisomy 16 mouse model of Down syndrome does not correct cardiac or craniofacial development anomalies,”
    115. (2003). Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory,”
    116. (2009). S.Levine,A.Saltzman,E.Levy,andS.D.Ginsberg,“Systemic pathology in aged mouse models of Down’s syndrome and Alzheimer’s disease,”
    117. (2009). Sah´ un et al., “A new mouse model for the trisomy of the Abcg1-U2af1 region reveals the complexity of the combinatorial genetic code of down syndrome,”
    118. (2009). Salazar-Colocho et al., “Overexpression of wild-type human APP in mice causes cognitive deficits and pathological features unrelated to Aβ levels,”
    119. (2003). Sanij et al., “ETS2 overexpression in transgenic models and in Down sydrome predisposes to apoptosis via the p53 pathway,”
    120. (1989). Scartezzini,“ExpressionofthehumanETS-2oncogeneinnormalfetal tissues and in the brain of a fetus with trisomy 21,” Human Genetics,
    121. (1990). Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome,” in
    122. (2006). Synapse formation and function is modulated by the amyloid precursor protein,”
    123. (2007). Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotypephenotype relationships,”
    124. (2008). Synaptojanin 1-linked phosphoinositide dyshomeostasis and cognitive deficits in mouse models of Down’s syndrome,”
    125. (1977). Synteny betweenglycinamideribonucleotidesynthetaseandsuperoxide dismutase (soluble),”
    126. (1988). The gene for cystathionine β-synthase (CBS) maps to the subtelomeric region on human chromosome 21q and to proximal mouse chromosome 17,”
    127. The growth capacity of bone marrow CD34 positive cells in culture is drastically reduced in a murine model of Down syndrome,”
    128. (1973). The linkage of genesforthehumaninterferon-inducedantiviralproteinand indophenoloxidase-BtraitstochromosomeG-21,”Journalof Experimental Medicine,
    129. (2004). The relationship of patient age to the pathobiology of the clonal myeloid diseases,”
    130. (2008). The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells,”
    131. (2011). Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions,”
    132. (2007). Transcriptional regulation of telomerase activity: roles of the the ets transcription factor family,”
    133. (2007). Trisomy for the Down syndrome “critical region” is necessary but not sufficient for brain phenotypes of trisomic mice,”
    134. (2010). Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome,”
    135. (2008). Trisomy represses ApcMin-mediated tumours in mouse models of Down’s syndrome,”
    136. (1998). Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities,”
    137. (2010). Tumour angiogenesis is reduced
    138. (1996). Tymms et al., “Down’s syndrome-like skeletal abnormalities
    139. (2001). v a nd e rW i l t ,H .H .J .B a c k u s ,K .S m i de ta l . , “Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors,”
    140. (2010). Variation in folate pathway genes contributes to risk of congenital heart defects among individuals with Down syndrome,”
    141. (2008). Vitamin E for Alzheimer’s disease and mild cognitive impairment,”
    142. (1975). W i l l i a m s ,R .L .S u m m i t t ,P .R .M a r t e n s ,a n dR .A . Kimbrell, “Familial Down syndrome due to t(10;21) translocation: evidence that the Down phenotype is related to trisomy of a specific segment of chromosome 21,”
    143. (1989). W.H.Meck,R.A.Smith,andC.L.Williams,“Organizational changes in cholinergic activity and enhanced visuospatial memory as a function of choline administered prenatally or postnatally or both,”
    144. (2010). Why vitamin e therapy fails for treatment of Alzheimer’s disease,”
    145. (2011). α-Tocopherol suppresses lipid peroxidation and behavioral and cognitive impairments

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.